Holding(s) in Company (1116Z)
March 12 2012 - 3:00AM
UK Regulatory
TIDMHIK
RNS Number : 1116Z
Hikma Pharmaceuticals Plc
11 March 2012
Notification of Major Interests in Shares
LONDON, 11 March 2012 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK), the fast growing multinational
pharmaceuticals group, announces as follows:
1 Identity of the issuer or the underlying Hikma Pharmaceuticals PLC
issuer of existing shares to which the
voting rights are attached
2 Reason for the notification
An acquisition or disposal of voting Yes
rights
------------------------------------------------- ----
An acquisition or disposal of financial No
instruments which may result in the acquisition
of shares already issues to which voting
rights are attached
------------------------------------------------- ----
An event changing the breakdown of voting No
rights
------------------------------------------------- ----
Other (please specify): Compliance with No
the Transparency Directive
------------------------------------------------- ----
3 Full name of the person subject to the Artio Global Management
notification obligation LLC
4 Full name of shareholders N/A
---------------------------------------- ------------------------
5 Date of the Transaction (and date on 8 March 2012
which the threshold crossed is reached
differently)
---------------------------------------- ------------------------
6 Date on which the issuer notified 9 March 2012
---------------------------------------- ------------------------
7 Threshold that is crossed 3%
---------------------------------------- ------------------------
8 Notified details (ABC)
A. Voting rights attached to shares
Class type Situation previous Resulting situation after the triggering
of shares to the triggering transaction
(if possible transaction
using the
ISIN code)
------------------------ --------------------------------------------------------------
Number Number Number of shares Number of voting % of voting
of shares of voting rights rights
rights
----------- ----------- --------------------- ------------------- ------------------
Direct Indirect Direct Indirect Direct Indirect
----------- ----------- ---------- --------- ------- ---------- ------- ---------
Ordinary
Shares (0.10
GBP)
GB00B0LCW083 5,889,282 5,889,282 5,874,223 0 0 5,874,223 0% 2.99%
----------- ----------- ---------- --------- ------- ---------- ------- ---------
B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial Expiration Exercise/Conversion Number of voting % of voting rights
instrument Date Period/Date rights that may
be acquired if
the instrument
if exercised/converted
----------- -------------------- ------------------------ -------------------
- - - - -
----------- -------------------- ------------------------ -------------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
Resulting situation after the triggering transaction
Type of Exercise Expiration Exercise/Conversion Number of voting % of voting rights
financial Price Date Period/Date rights instrument
instrument refers to
--------- ----------- -------------------- ------------------- ---------------------
Nominal Delta
--------- ----------- -------------------- ------------------- ----------- --------
- - - - - - -
--------- ----------- -------------------- ------------------- ----------- --------
Total A+B+C
Number of Voting rights % of voting rights
-------------------
5,874,223 2.99%
-------------------
9 Chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held, if applicable
Artio Global Management LLC acts as investment manager exercising proxy voting rights
on behalf
of independent beneficial owners.
---------------------------------------------------------------------------------------
Proxy Voting
10 Name of the proxy holder Artio Global Management
LLC
-------------------------------------- ------------------------
11 Number of voting rights proxy holder N/A
will cease to hold
-------------------------------------- ------------------------
12 Date on which proxy holder will cease N/A
to hold voting rights
-------------------------------------- ------------------------
13 Additional Information
14 Contact name: Donald Delano
Chief Compliance Officer
-------------------------- --------------------------
15 Contact telephone number: +1 (212) 297 3628
-------------------------- --------------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed pharmaceutical
products. Hikma's operations are conducted through three
businesses: "Branded", "Injectables" and "Generics". Hikma's
operations are based principally in the Middle East and North
Africa ("MENA") region, where it is a market leader and sells
across 17 countries, the United States and Europe. In 2010, the
Group achieved revenues of $731 million (2009 $637 million) and
profit attributable to shareholders of $99 million (2009 $78
million).
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUAUSRUNAOAAR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
